Piper Sandler Reiterates Overweight on Sutro Biopharma, Maintains $11 Price Target

Benzinga · 10/11 17:56
Piper Sandler analyst Edward Tenthoff reiterates Sutro Biopharma (NASDAQ:STRO) with a Overweight and maintains $11 price target.